Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
"Our findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity, and that this effect is independent from weight loss," conclude the authors, who hail from the University of Naples in Italy
That is a fundamentally different goal than "lose weight as fast as possible." It's harder, slower on the scale, and produces dramatically better results in the mirror and in long-term health
This is where the right tools can make all the difference
Current status: TRIUMPH-4 results available: December 2025 readout showing 28.7% weight loss at 68 weeks (Giblin et al., PMID 41090431) Additional TRIUMPH trials: Expected to report results through 2026, including TRIUMPH-Outcomes (cardiovascular endpoints, NCT06383390, completion Feb 2029) NDA submission timing: Eli Lilly must compile the full trial package before submitting
Early studies indicate GLP-1s should be researched further as possible treatments for alcohol use and substance use disorders, nicotine addiction, and compulsive behaviors
US$ 21.87
US$ 20.54
US$ 25.59
US$ 21.06
US$ 26.29
US$ 28.18
